We acted as Greek legal counsel for MS Pharma, a leading pharmaceuticals and healthcare solutions company in the Middle East based in Amman, Jordan, which also operates in Turkey and Africa, in the acquisition of the Greek-based generics company Genepharm S.A. in the context of MS Pharma’s expansion into Europe and farther afield. Genepharm develops, manufactures and out-licenses high-value generic pharmaceutical products.  The transaction, which was completed on 30.04.2019, required extensive and specialised  legal due diligence in relation to pharmaceutical products and services, as well as complex corporate matters for a Greek company founded on and active since 1967, an in-depth analysis of the commercial relationships and agreements of Genepharm with other pharmaceutical companies and customers in Greece and abroad with regards to the licensing (in and out) and rights of use of generics’ dossiers, distribution of generics and intellectual property matters in the highly regulated pharmaceutical sector, while in parallel our team worked together with the international legal advisors in drafting, negotiating and concluding the share purchase agreement and other transaction documents. The transaction is one of the significant M&A transactions in Greece for Q1 2019 and in the Greek pharmaceuticals sector.